Characterization and comparison of efficacy and safety of calcipotriene and clobetasol in severe chronic plaque psoriasis patients

Manohar Yazali; Shalini Chandra; Amarendar Sura

doi:10.53730/ijhs.v6nS5.11824

Authors

Manohar Yazali
yazalimanohar@gmail.com
Ph.D. Research Scholar, Bareilly International University, Department of Pharmacology, Rohilkhand Medical College & Hospital, Bareilly, Uttar Pradesh, India
Shalini Chandra Professor & Head Department of Pharmacology, Rohilkhand Medical College & Hospital Bareilly, Uttar Pradesh, India
Amarendar Sura Assistant Professor Department of Pharmacology, NAMO Medical Education and Research Institute, Silvasa, DNH, India

Keywords:

Plaque psoriasis, Calcipotriene, Clobetasol

Abstract

Calcipotriene and Clobetasol ointments efficiently treat psoriasis. The purpose of the study was to characterize and compare the efficacy and safety of Calcipotriene and Clobetasol in chronic plaque psoriasis patients. 70 patients with chronic plaque psoriasis were recruited and randomly divided into two groups of 35 each. One group received 0.005% Calcipotriene, and the other group received 0.05% clobetasol twice daily for 12 weeks. Efficacy evaluations comprise global improvement assessed by the clinician by using the Physician Global Assessment (PGA) score. Efficacy further included the 'Dermatological Sum Score' (DSS) and Psoriasis Area and Severity Index (PASI) score at each study visit. The safety evaluations included clinical assessment of cutaneous safety and assessment of cutaneous discomfort by the clinician as well as the subject. Calcipotriene and Clobetasol were significantly effective in reducing PASI and DSS. However, the two experimental groups have shown no statistically significant observations. The PGA score assessed clinically was 1.27 for calcitriene and 1.79 for Clobetasol (p>0.05). The cutaneous safety score was higher in the clobetasol group compared to the Calcipotriene group. 4% of cutaneous discomfort was reported with Clobetasol compared to 2% with Calcipotriene. Calcipotriene showed a better safety profile than Clobetasol.

Downloads

Download data is not yet available.

References

Abramovits, W. (2009). Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy. Journal of Drugs in Dermatology: JDD, 8(8 Suppl), s17-22.

Alora-Palli, M. B., Kimball, A. B., & Van Cott, A. (2009, March). A new topically applied liquor carbonis distillate (coal tar) solution helps reduce regression of plaque psoriasis after 12 weeks (about 3 months) of treatment: A 6-week comparison to Calcipotriene cream. In Journal of the American Academy of Dermatology (Vol. 60, No. 3, pp. AB174-AB174).

Alora-Palli, M. B., Perkins, A. C., Van Cott, A., & Kimball, A. B. (2010). Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis. American journal of clinical dermatology, 11(4), 275-283.

Bai, K. S., & Naik, P. S. (2015). An open label prospective randomized trial to compare the efficacy of salicylic acid ointment 3% versus betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis. Journal of Evolution of Medical and Dental Sciences, 4(36), 6296-6303.

Brouda, I., Edison, B., Van Cott, A., & Green, B. A. (2010). Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis. Cutis, 85(4), 214–220.

Dewi, L. K. C., Kawiana, I. G. P., & Martini, L. K. B. (2018). Integrative model of performance improvement. International Journal of Social Sciences and Humanities, 2(2), 26–39. https://doi.org/10.29332/ijssh.v2n2.116

Feldman, S. R., Matheson, R., Bruce, S., Grande, K., Markowitz, O., Kempers,S., & Wyres, M. (2012). Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis. American journal of clinical dermatology, 13(4), 261-271.

Fleming, C., Ganslandt, C., Guenther, L., Johannesson, A., Buckley, C., Simon,J. C., & Tingleff, L. V. (2010). Calcipotriene plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. European Journal of Dermatology, 20(4), 465-471.

Girolomoni, G., Vena, G. A., Ayala, F., Cannavò, S. P., De Pità, O., Chimenti, S., & Peserico, A. (2012). Consensus on the use of the fixed combination Calcipotriene/betamethasone dipropionate in the treatment of plaque psoriasis. Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Societa Italiana di Dermatologia e Sifilografia, 147(6), 609-624.

Goruntla, N., Arakala, G. K., Nelluri, G. P., Mounika, K. N., Pujari, S., & Byalla,M. K. (2018). Comparison of efficacy, safety, and cost-effectiveness of topical salicylic acid 6% versus clobetasol propionate 0.05% in the treatment of limited chronic plaque psoriasis. Journal of Health Research and Reviews, 5(2), 86.

Hendriks, A. G. M., Keijsers, R. R. M. C., de Jong, E. M. G. J., Seyger, M. M. B., & vande Kerkhof, P. C. M. (2013). Efficacy and safety of combinations of first‐line topical treatments in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology,27(8), 931-951.

Kaur, I., Dogra, S., Jain, R., & Kumar, B. (2008). Comparative study of Calcipotriene (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. Indian Journal of Dermatology, Venereology, and Leprology, 74(5), 471 -4

Kircik, L. (2009). Efficacy and safety of topical calcitriol 3 microg/g ointment, a new topical therapy for chronic plaque psoriasis. Journal of Drugs in Dermatology: JDD, 8(8 Suppl), s9-16.

Mahajan, H., Deshmukh, G., Dhoot, D., Mamadi, R., & Barkate, H. (2020). Comparative Clinical Assessment of Effectiveness and Safety of Calcitriol and Calcipotriene in Mild Plaque Psoriasis. Int. J. Clin. Dermatol, 3, 28-31.

Mason, A. R., Mason, J., Cork, M., Dooley, G., & Hancock, H. (2013). Topicaltreatments for chronic plaque psoriasis. Cochrane Database of Systematic Reviews, (3).

Mehta, S., Singal, A., Singh, N., & Bhattacharya, S. (2009). A study of clinicohistopathological correlation in patients of psoriasis and psoriasiform dermatitis. Indian Journal of Dermatology, Venereology and Leprology, 75(1), 100.

Sarma, N. (2017). Evidence and suggested therapeutic approach in psoriasis of difficult-to-treat areas: Palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and intertriginous psoriasis. Indian Journal of Dermatology, 62(2), 113.

Sembiring, T. B., Maruf, I. R., Susilo, C. B., Hidayatulloh, A. N., & Bangkara, B. M. A. S. A. (2022). Health literacy study on approaching forest and boosting immune system strategy. International Journal of Health Sciences, 6(1), 40–49. https://doi.org/10.53730/ijhs.v6n1.3145

Sofen, H., Hudson, C. P., Cook-Bolden, F. E., Preston, N., Colón, L. E.,Caveney, S. W., & Gottschalk, R. W. (2011). Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology: JDD, 10(8), 885-892.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949

Yan, R., Jiang, S., Wu, Y., Gao, X. H., & Chen, H. D. (2016). Topical Calcipotriene/betamethasone dipropionate for psoriasis vulgaris: A systematic review. Indian journal of dermatology, venereology and leprology, 82(2).